What if we could stop disease-causing proteins before they're even made—using small molecules to target their mRNA?

David Weitz, CEO of Syrna Therapeutics, is pioneering exactly that: 3D structure-guided drug discovery for mRNA, coupled with covalent translation inhibitors that silence proteins at the source.

🎙️ Full episode drops 7 January 2026

In the complete interview, we dive into:

• Why mRNA is an untapped drug target

• 3D structure-guided discovery and covalent inhibitors

• Lead programs in immunology and neurodegeneration

• Building Syrna and coming out of stealth

Subscribe so you don't miss it.

#SneakPeek #mRNA #DrugDiscovery #Biotech